Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigvotatug vedotin in Chinese patients with advanced solid tumors
NCT06549816Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 3 more, sponsored by Pfizer. Primary endpoints: Adverse Events, Laboratory Abnormalities and 1 more. Started Aug 2024; status: completed.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06549816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549816.